Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    ImmunityBio Inc.

    NASDAQ: IBRX · Real-Time Price · USD
    2.75
    0.09 (3.38%)
    At close: Jun 02, 2025, 10:31 AM
    3.38%
    Bid 2.75
    Market Cap 2.43B
    Revenue (ttm) 31.22M
    Net Income (ttm) -409.1M
    EPS (ttm) -0.57
    PE Ratio (ttm) -4.83
    Forward PE -8.97
    Analyst Buy
    Ask 2.76
    Volume 4,234,232
    Avg. Volume (20D) 8,358,047.8
    Open 2.77
    Previous Close 2.66
    Day's Range 2.70 - 2.87
    52-Week Range 1.83 - 7.63
    Beta -0.10

    About IBRX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IBRX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 week ago
    +3.57%
    ImmunityBio shares are trading higher after Piper ... Unlock content with Pro Subscription
    2 weeks ago
    +14.01%
    ImmunityBio shares are trading higher after the company reported better-than-expected Q1 sales results.
    news image

    Just now · businesswire.com

    ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access au...

    news image

    5 days ago · businesswire.com

    ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

    CULVER CITY, Calif. & RIYADH, Saudi Arabia--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the signing of a strategic Memorandum of Understanding (...

    news image

    2 weeks ago · zacks.com

    ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

    ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    2 weeks ago · zacks.com

    ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

    ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.

    news image

    2 weeks ago · businesswire.com

    ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) ...

    news image

    3 weeks ago · seekingalpha.com

    ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

    ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX sha...

    news image

    3 weeks ago · benzinga.com

    ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

    ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA p...

    news image

    3 weeks ago · businesswire.com

    ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and...

    news image

    1 month ago · zacks.com

    ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · seekingalpha.com

    ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

    ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision fo...

    Add to Watchlist